Elevated levels of plasma transforming growth factor-β1 in idiopathic and heritable pulmonary arterial hypertension

International Journal of Cardiology

Volumn 222, Issue , 2016, Pages 368-374

  Yan, Yi ^a   Wang, Xiao Jian ^b   Li, Su Qi ^b   Yang, Shu Hui ^b   Lv, Zi Chao ^b   Wang, Li Ting ^b   He, Yang Yang ^b   Jiang, Xin ^b   Wang, Yong ^c   Jing, Zhi Cheng ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUWAI HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Pulmonary arterial hypertension; Survival; Transforming growth factor 1

Indexed keywords

BIOLOGICAL MARKER; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HEART DISEASE; HERITABLE PULMONARY ARTERIAL HYPERTENSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIGNAL TRANSDUCTION; BLOOD; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FOLLOW UP; YOUNG ADULT;

ADULT; BIOMARKERS; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84982667893     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.192     Document Type: Article

References (32)

1. [1] Benza, R.L., Miller, D.P., Barst, R.J., Badesch, D.B., Frost, A.E., McGoon, M.D., An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest 142 (2012), 448–456.
2. [2] Tajsic, T., Morrell, N.W., Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension. Comput. Phys. 1 (2011), 295–317.
3. [3] Blobe, G.C., Schiemann, W.P., Lodish, H.F., Role of transforming growth factor beta in human disease. N. Engl. J. Med. 342 (2000), 1350–1358.
4. [4] Khan, R., Agrotis, A., Bobik, A., Understanding the role of transforming growth factor-beta1 in intimal thickening after vascular injury. Cardiovasc. Res. 74 (2007), 223–234.
5. [5] Massague, J., Blain, S.W., Lo, R.S., TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103 (2000), 295–309.
6. [6] Upton, P.D., Davies, R.J., Tajsic, T., Morrell, N.W., Transforming growth factor-beta(1) represses bone morphogenetic protein-mediated Smad signaling in pulmonary artery smooth muscle cells via Smad3. Am. J. Respir. Cell Mol. Biol. 49 (2013), 1135–1145.
7. [7] Yang, X., Long, L., Southwood, M., et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ. Res. 96 (2005), 1053–1063.
8. [8] Biasin, V., Chwalek, K., Wilhelm, J., et al. Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. Int. J. Biochem. Cell Biol. 54 (2014), 137–148.
9. [9] Vizza, C.D., Letizia, C., Badagliacca, R., et al. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. Int. J. Cardiol. 167 (2013), 220–224.
10. [10] Graham, B.B., Chabon, J., Gebreab, L., et al. Transforming growth factor-beta signaling promotes pulmonary hypertension caused by Schistosoma mansoni. Circulation 128 (2013), 1354–1364.
11. [11] Long, L., Crosby, A., Yang, X., et al. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 119 (2009), 566–576.
12. [12] Perkett, E.A., Lyons, R.M., Moses, H.L., Brigham, K.L., Meyrick, B., Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension. J. Clin. Invest. 86 (1990), 1459–1464.
13. [13] Rath, D., Chatterjee, M., Muller, I., et al. Platelet expression of transforming growth factor beta 1 is enhanced and associated with cardiovascular prognosis in patients with acute coronary syndrome. Atherosclerosis 237 (2014), 754–759.
14. [14] Suthanthiran, M., Gerber, L.M., Schwartz, J.E., et al. Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans. Kidney Int. 76 (2009), 72–80.
15. [15] Galie, N., Humbert, M., Vachiery, J.L., et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 37 (2016), 67–119.
16. [16] Li, R.K., Li, G., Mickle, D.A., et al. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 96 (1997), 874–881.
17. [17] Peterson, M.C., Circulating transforming growth factor beta-1: a partial molecular explanation for associations between hypertension, diabetes, obesity, smoking and human disease involving fibrosis. Med. Sci. Monit. 11 (2005), RA229–RA232.
18. [18] Soon, E., Holmes, A.M., Treacy, C.M., et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122 (2010), 920–927.
19. [19] Rhodes, C.J., Wharton, J., Howard, L.S., Gibbs, J.S., Wilkins, M.R., Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart 97 (2011), 1054–1060.
20. [20] Quarck, R., Nawrot, T., Meyns, B., Delcroix, M., C-reactive protein. J. Am. Coll. Cardiol. 53 (2009), 1211–1218.
21. [21] Chen, C., Lei, W., Chen, W., et al. Serum TGF-beta1 and Smad3 levels are closely associated with coronary artery disease. BMC Cardiovasc. Disord., 14, 2014, 18.
22. [22] Wang, S., Han, X., Hu, X., et al. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin. Chim. Acta 430 (2014), 63–70.
23. [23] Hein, S., Arnon, E., Kostin, S., et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107 (2003), 984–991.
24. [24] Kuwahara, F., Kai, H., Tokuda, K., et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106 (2002), 130–135.
25. [25] Rosenkranz, S., Flesch, M., Amann, K., et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am. J. Physiol. Heart Circ. Physiol. 283 (2002), H1253–H1262.
26. [26] Brooks, W.W., Conrad, C.H., Myocardial fibrosis in transforming growth factor beta(1)heterozygous mice. J. Mol. Cell. Cardiol. 32 (2000), 187–195.
27. [27] Matsumoto-Ida, M., Takimoto, Y., Aoyama, T., Akao, M., Takeda, T., Kita, T., Activation of TGF-beta1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am. J. Physiol. Heart Circ. Physiol. 290 (2006), H709–H715.
28. [28] See, F., Thomas, W., Way, K., et al. P38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J. Am. Coll. Cardiol. 44 (2004), 1679–1689.
29. [29] Lal, H., Ahmad, F., Zhou, J., et al. Cardiac fibroblast glycogen synthase kinase-3beta regulates ventricular remodeling and dysfunction in ischemic heart. Circulation 130 (2014), 419–430.
30. [30] Pan, Z., Sun, X., Shan, H., et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 126 (2012), 840–850.
31. [31] Nagalingam, R.S., Sundaresan, N.R., Noor, M., Gupta, M.P., Solaro, R.J., Gupta, M., Deficiency of cardiomyocyte-specific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor beta (TGFbeta1)-dependent paracrine mechanism. J. Biol. Chem. 289 (2014), 27199–27214.
32. [32] Sklepkiewicz, P., Schermuly, R.T., Tian, X., et al. Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. PLoS One, 6, 2011, e18883.